KU
Kura Oncology, Inc.
KURA · NASDAQ
$11.20 -0.97% (-$0.11)
1M -8.35%
Market Cap $994.3M
P/E Ratio -
Div. Yield -
ROE 207.18%
Bulios Fair Price
$15.63
39.6% upside
Trenutna cena
$11.2
Podcenjeno Poštena vrednost Precenjeno
Po podatkih Bulios Fair Price je delnica KURA trenutno podcenjena glede na svojo tržno ceno. Kako deluje?
Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?
Piotroski F-Score Weak
3/9Valuation
0 /100
Expensive P/B 20.53x
P/S 12.88x
P/FFO N/A
Growth
0 /100
Declining Book val. growth 25.45%
FCF growth N/A
EPS growth N/A
Profitability
20 /100
Weak Op. margin 411.90%
Gross margin 94.73%
FCF margin 152.06%
Quality
2 /100
Poor ROA 50.49%
ROIC 66.97%
Asset turnover 0.13x
Debt
61 /100
Moderate Int. coverage -208.21x
Debt/Equity 0.50x
Current ratio 4.73x
Stability
43 /100
Moderate Profitable years 0
Beta 0.38x
EPS volatility 33.38%
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o KURA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Troy Wilson
Employees
260
Headquarters
San Diego
Prihajajoči dogodki
03 NOV.
Earnings
Upcoming earnings report